We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 24, 2021

Measurable Residual Disease Status and Outcome of Transplant in Acute Myeloid Leukemia in Second Complete Remission

Blood Cancer Journal

 

Additional Info

Blood Cancer Journal
Measurable Residual Disease Status and Outcome of Transplant in Acute Myeloid Leukemia in Second Complete Remission: A Study by the Acute Leukemia Working Party of the EBMT
Blood Cancer J 2021 May 12;[EPub Ahead of Print], MH Gilleece, A Shimoni, M Labopin, S Robinson, D Beelen, G Socié, A Unal, A Ganser, A Vitek, H Sengeloev, I Yakoub-Agha, E Tholouli, E Polge, M Mohty, A Nagler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading